Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. RadioGel™
  2. Human Clinical Trials

Human Clinical Trials (future)

the next step in the evolution of RadioGel™ – Precision Radionuclide Therapy (PRnT)

Human Clinical Trials

We're actively engaged with the USA FDA on our Pre-Submission Investigational Device Exemption for RadioGel™. Once the completed application is finalized, and submited; upon approval we're planning to begin by treating thyroid cancer lymph nodes.

RadioGel™ is a precision radionuclide therapy device for delivering therapeutic radiation into solid metastatic tumors in the lymph nodes associated with papillary thyroid cancer which are accessible by percutaneous direct needle injection in patients who are not surgical candidates or who have declined surgery.


Updates Contact

Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy™ (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Precision Radionuclide Therapy (PRnT)
  • Research (White Papers)
  • US FDA IDE Application Updates
  • US FDA IDE Pre-Submission Process
  • Human Clinical Trials
  • Scroll to top